376
Participants
Start Date
May 12, 2023
Primary Completion Date
September 1, 2026
Study Completion Date
January 1, 2027
Botox 50 Unit Injection
Participants will be randomized to either receive a standard dose (100 units) or reduced dose (50 units) of onabotulinumtoxinA. If a participant has decreased symptom relief they may receive repeat treatment up to twice during the 12 month follow-up period, with minimum 4 month intervals between treatments.
Botox 100 Unit Injection
Participants will be randomized to either receive a standard dose (100 units) or reduced dose (50 units) of onabotulinumtoxinA. If a participant has decreased symptom relief they may receive repeat injection up to twice during the 12 month follow-up period, with minimum 4 month intervals between treatments.
RECRUITING
University of Pittsburgh Medical Center, Pittsburgh
RECRUITING
University of Alabama - Birmingham, Birmingham
RECRUITING
University of Nebraska Medical Center, Omaha
RECRUITING
University of Texas Southwestern Medical Center, Dallas
RECRUITING
Kaiser Permanente Medical Group, San Diego
RECRUITING
Oregon Health & Science University, Portland
RECRUITING
Dartmouth-Hitchcock Medical Center, Lebanon
Patient-Centered Outcomes Research Institute
OTHER
Dartmouth College
OTHER
University of Alabama at Birmingham
OTHER
University of Pittsburgh
OTHER
University of Texas
OTHER
Kaiser Permanente
OTHER
Oregon Health and Science University
OTHER
Stanford University
OTHER
University of Connecticut
OTHER
University of Nebraska
OTHER
Dartmouth-Hitchcock Medical Center
OTHER